<DOC>
	<DOC>NCT01730508</DOC>
	<brief_summary>This multicenter, prospective, observational study will evaluate the use in clinical practice and the efficacy and safety of Pegasys (peginterferon alfa-2a) in Chinese participants with HBeAg negative chronic hepatitis B. Participants receiving Pegasys according to the local label will be followed for the duration of their treatment and for one year after cessation of treatment.</brief_summary>
	<brief_title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participants, &gt;/= 18 years of age Treatment with Pegasys according to label and standard clinical practice HBeAg negative serologically proven chronic hepatitis B with or without cirrhosis Serum alanine aminotransferase (ALT) &gt; upper limit of normal (ULN) but &lt;/= 10 x ULN Hepatitis B Virus (HBV) DNA &gt;/= 2000 IU/mL Contraindications to Pegasys as detailed in the label Coinfection with hepatitis A, hepatitis C or HIV Pregnant or lactating women Participants should not receive concomitant therapy with telbivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>